Co-Clinical Trial Approach to Targeting the PI3K Pathway in Prostate Cancer


Dr. Akash Patnaik, assistant professor of medicine, discusses the rationale for PI3k as a therapeutic target in prostate cancer and the mechanistic strategies to overcome de novo and acquired resistance to single agent PI3K inhibitors in co-clinical trials of prostate cancer.  Dr. Patnaik also examines “co-clinical” PI3K inhibitor-based combination trials in PTEN-deficient prostate cancer.



Akash Patnaik

Akash Patnaik, MD, PhD

Assistant Professor of Medicine

Admissions, Referrals and Consultations:

Call UCM Physician Connect at
Contact Us

Sign Up for Email Newsletters

Learn more >